Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 1.00 |
| ▸ | BCHE | P06276 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146771 | 0.80 | BCHE (1.00) | ACHEBCHECHRM4 | |
| SCHEMBL3155847 | 0.76 | ACHE (1.00) | ACHEBCHEKDM4ECHRM4 | |
| SCHEMBL6496336 | 0.75 | CCR8 (0.69) | ACHEBCHEKDM4EMEN1ALDH1A1 | |
| SCHEMBL429213 | 0.75 | ACHE (0.74) | ACHEBCHE | |
| SCHEMBL3147014 | 0.75 | BCHE (1.00) | ACHEBCHECHRM4 | |
| SCHEMBL10778328 | 0.74 | L3MBTL1 (0.60) | ACHEBCHEMEN1KMT2A | |
| SCHEMBL3157204 | 0.74 | BCHE (1.00) | ACHEBCHEMEN1KMT2ACHRM4 | |
| SCHEMBL429212 | 0.73 | ACHE (0.74) | ACHEBCHECHRM4 | |
| SCHEMBL4636524 | 0.73 | ACHE (0.74) | ACHEBCHECHRM4 | |
| SCHEMBL4636527 | 0.73 | ACHE (0.74) | ACHEBCHECHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758888-B1 | BUTYRYLCHOLINESTERASE SELECTIVE INHIBITORS | NEUROPHARMA S A U (ES) | 2010-02-17 | — | — | EP | disclosed |
| US-20080119521-A1 | Butyrlcholinesterase Selective Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-05-22 | — | — | US | disclosed |
| US-20080119521-A1 | Butyrlcholinesterase Selective Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-05-22 | — | — | US | disclosed |
| US-20080119521-A1 | Butyrlcholinesterase Selective Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-05-22 | — | — | US | disclosed |
| CN-1960986-A | Butyrylcholinesterase selective inhibitors | NEUROPHARMA S A U (ES) | 2007-05-09 | — | — | CN | disclosed |
| EP-1758888-A1 | BUTYRYLCHOLINESTERASE SELECTIVE INHIBITORS | Neuropharma S.A.U. (ES) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118570-A1 | BUTYRYLCHOLINESTERASE SELECTIVE INHIBITORS | NEUROPHARMA, S.A. (ES) | 2005-12-15 | — | — | WO | disclosed |
| EP-1600447-A1 | Butyrylcholinesterase selective inhibitors | Neuropharma S.A.U. (ES) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119521-A1 | Butyrlcholinesterase Selective Inhibitors | BCHE, ACHE, BACE1 | ACHE 2/4885BCHE 1/4885KDM4E 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.